Organon & Co.: Hypercholesterolemia trials

The registry lists 95 Hypercholesterolemia studies with Organon & Co. as lead sponsor. 0 are open to participants now and 44 have results posted.

Phase 1 3Phase 3 61Phase 4 18No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)CompletedNCT03768427Phase 3Results posted
• A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)CompletedNCT02748057Phase 3Results posted
• A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)CompletedNCT02741245Phase 3Results posted
• A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)CompletedNCT02550288Phase 3Results posted
• A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)CompletedNCT02460159Phase 3Results posted
• A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)CompletedNCT01611883Phase 4Results posted
• A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)CompletedNCT01414192Results posted
• Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)CompletedNCT01381679Results posted
• A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)CompletedNCT01370603Phase 3Results posted
• A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)CompletedNCT01370590Phase 3Results posted
• A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)CompletedNCT01333436Not applicableResults posted
• MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)CompletedNCT01154036Phase 3Results posted
• Vytorin Reexamination Study (0653A-174)CompletedNCT01070966Results posted
• EZETROL® Re-examination Study (MK0653-175)(COMPLETED)CompletedNCT01070953Results posted
• Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)CompletedNCT00909389Results posted
• Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)CompletedNCT00867165Phase 3Results posted
• A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)CompletedNCT00783263Phase 3Results posted
• Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)CompletedNCT00782184Phase 3Results posted
• Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)CompletedNCT00730132Results posted
• Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)CompletedNCT00724477Results posted
• Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)CompletedNCT00705081Results posted
• Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)CompletedNCT00704535Results posted
• Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)CompletedNCT00654628Phase 4Results posted
• Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)CompletedNCT00654095Phase 3Results posted
• Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia (P05457)CompletedNCT00653523Phase 3Results posted
• Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)CompletedNCT00652327Phase 4Results posted
• A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)CompletedNCT00535405Phase 3Results posted
• A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea (0653A-129)(COMPLETED)CompletedNCT00496730Phase 3Results posted
• A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)CompletedNCT00479713Phase 3Results posted
• A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)CompletedNCT00462748Phase 3Results posted
• Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)CompletedNCT00442897Phase 4Results posted
• The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)CompletedNCT00423579Phase 4Results posted
• Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)CompletedNCT00423488Phase 3Results posted
• Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)CompletedNCT00418834Phase 3Results posted
• Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)CompletedNCT00413972Phase 3Results posted
• Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)CompletedNCT00409773Phase 3Results posted
• Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)CompletedNCT00319449Phase 4Results posted
• To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)CompletedNCT00276484Phase 3Results posted
• To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)CompletedNCT00276458Phase 3Results posted
• To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)CompletedNCT00271817Phase 3Results posted
• IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)CompletedNCT00202878Phase 3Results posted
• Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)CompletedNCT00166504Phase 4Results posted
• Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)CompletedNCT00129402Phase 3Results posted
• A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)CompletedNCT00101439Phase 3Results posted
• Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)CompletedNCT03885921Phase 3
• Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)CompletedNCT03884452Phase 3
• A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)CompletedNCT03882996Phase 3
• A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)CompletedNCT03882905Phase 3
• Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)CompletedNCT03882892Phase 3
• Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)CompletedNCT03867318Phase 3
• An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)CompletedNCT03867110Phase 3
• Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)CompletedNCT00723723
• A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)CompletedNCT00705211
• A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)CompletedNCT00704444
• Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)CompletedNCT00653913Phase 1
• Ezetimibe Plus Simvastatin Versus Simvastatin in Untreated Subjects With High Cholesterol (P03435)CompletedNCT00653835Phase 4
• Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With High Cholesterol (P03434)CompletedNCT00653796Phase 4
• Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)CompletedNCT00652847Phase 4
• Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial (0653-151)CompletedNCT00652444Phase 4
• Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)CompletedNCT00652431Phase 1
• Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)CompletedNCT00651404Phase 3
• Effect of Ezetimibe Plus Simvastatin on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (Study P03336)TerminatedNCT00651391Phase 3
• Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)TerminatedNCT00651378Phase 4
• Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)CompletedNCT00651274Phase 4
• Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)CompletedNCT00651144Phase 1
• Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)TerminatedNCT00651014Phase 4
• Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED)CompletedNCT00650819Phase 3
• Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)CompletedNCT00650689Phase 3
• Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377)CompletedNCT00650663Phase 4
• Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)CompletedNCT00552097Phase 3
• Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)CompletedNCT00457275Phase 3
• To Evaluate the Lipid-Lowering Efficacy and Safety of Simvastatin 40 Mg Tablet In Patients With Hypercholesterolemia (0733-264)CompletedNCT00398294Phase 4
• Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)CompletedNCT00395473Phase 3
• TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)CompletedNCT00328523Phase 3
• Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)CompletedNCT00202904Phase 4
• Ezetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)CompletedNCT00157924Phase 4
• A Study to Evaluate Ezetimibe in Korean Patients With Primary Hypercholesterolemia (0653-042)CompletedNCT00157911Phase 3
• A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)CompletedNCT00132717Phase 3
• A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)CompletedNCT00110435Phase 3
• A Study to Evaluate an Investigational Drug in Patients With Mixed Hyperlipidemia (0653A-071)(COMPLETED)CompletedNCT00093899Phase 3
• Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)TerminatedNCT00092833Phase 3
• Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)CompletedNCT00092716Phase 3
• MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)CompletedNCT00092690Phase 3
• An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)CompletedNCT00092664Phase 3
• A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)CompletedNCT00092651Phase 3
• An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)CompletedNCT00092638Phase 3
• Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)CompletedNCT00092625Phase 3
• Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)CompletedNCT00092612Phase 3
• Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)CompletedNCT00092599Phase 3
• Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)CompletedNCT00092586Phase 3
• Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)CompletedNCT00092573Phase 3
• Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)CompletedNCT00092560Phase 3
• Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)CompletedNCT00092157Phase 3
• Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Drugs in Patients With Elevated Cholesterol Levels (0653A-058)CompletedNCT00090298Phase 3
• Cholesterol Lowering Level of MK0653A+Simvastatin in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease (0653A-806)(COMPLETED)CompletedNCT00090168Phase 3